C.MatherK
Focus could improve, racing thoughts diminish, and motivation levels could increase
Study participants We identified all adult (aged 20 years) patients with NAFLD and type 2 diabetes who had newly started treatment with non-insulin glucose-lowering drugs (metformin, GLP-1RAs, SGLT2 inhibitors, sulfonylureas, meglitinides, thiazolidinediones, acarbose or dipeptidyl peptidase-4 inhibitors) between 1 January 2013 and 31 December 2021
State attorneys general have stepped into the gap, using consumer-protection theories to police misrepresentations, dangerous sourcing practices and improper use of research-grade materials
Take home message Success on GLP-1 medication isn't just about the number on the scale
Weight loss drug coverage does not apply automatically to every Medicare beneficiary